Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- Conditions
- Hypertension, Pulmonary
- Registration Number
- NCT01784562
- Lead Sponsor
- Bayer
- Brief Summary
The aim of the study is to assess safety, tolerability and clinical effects of different doses of riociguat in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and who are not satisfactorily treated and cannot participate in any other CTEPH trial. In the US the study runs as an Expanded Access program under 21 CFR 312.320.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Male and female patients with CTEPH either inoperable or with persistent or recurrent PH after surgery
Read More
Exclusion Criteria
- All types of pulmonary hypertension other than Dana Point Classification Group 4
- Operable patients listed for PEA (Pulmonary Endarterectomy)
Read More
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method